Biomarker analysis revealed elevated levels of amyloid peptides (both short and long), and Tau proteins in the CSF during the preclinical phase of AD, which clearly reflected the biomarker changes observed in patients with preclinical AD. Here, MAPT is linked to Alzheimer disease.